- Home
- SN vs EXEL Comparison
SN vs EXEL Comparison
Compare SN & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SN
- EXEL
- Stock Information
- Founded
- SN 1993
- EXEL 1994
- Country
- SN United States
- EXEL United States
- Employees
- SN N/A
- EXEL N/A
- Industry
- SN
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SN
- EXEL Health Care
- Exchange
- SN Nasdaq
- EXEL Nasdaq
- Market Cap
- SN 11.2B
- EXEL 9.8B
- IPO Year
- SN N/A
- EXEL 2000
- Fundamental
- Price
- SN $102.26
- EXEL $45.40
- Analyst Decision
- SN Strong Buy
- EXEL Buy
- Analyst Count
- SN 9
- EXEL 18
- Target Price
- SN $117.28
- EXEL $38.76
- AVG Volume (30 Days)
- SN 1.9M
- EXEL 3.3M
- Earning Date
- SN 05-08-2025
- EXEL 05-13-2025
- Dividend Yield
- SN N/A
- EXEL N/A
- EPS Growth
- SN 133.24
- EXEL 237.58
- EPS
- SN 3.16
- EXEL 2.20
- Revenue
- SN $5,685,049,000.00
- EXEL $2,298,922,000.00
- Revenue This Year
- SN $16.76
- EXEL $5.78
- Revenue Next Year
- SN $11.53
- EXEL $10.94
- P/E Ratio
- SN $32.35
- EXEL $20.59
- Revenue Growth
- SN 27.34
- EXEL 24.49
- 52 Week Low
- SN $60.50
- EXEL $20.14
- 52 Week High
- SN $123.00
- EXEL $40.26
- Technical
- Relative Strength Index (RSI)
- SN 70.36
- EXEL 73.08
- Support Level
- SN $98.80
- EXEL $34.90
- Resistance Level
- SN $104.97
- EXEL $48.85
- Average True Range (ATR)
- SN 3.45
- EXEL 1.81
- MACD
- SN 2.50
- EXEL 0.86
- Stochastic Oscillator
- SN 87.38
- EXEL 75.27
About SN SharkNinja Inc.
SharkNinja Inc is a product design and technology company that creates 5-star-rated lifestyle solutions through inventive products for consumers around the world. Its product categories include Cleaning, Cooking, Food Preparation, Home Environment and Beauty products. It sells vacuum cleaners, cooking pots, fryers, hair dryers, etc. The SharkNinja Group is expected to carry on the design, production, marketing, and distribution of the Shark and Ninja brands of small household appliances in North America, Europe and other selected international markets (excluding the Asia Pacific Region and Greater China). Currently, the majority of the revenue is derived from the U.S. market.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.